Jeff Rudy, Chief Operating Officer

Jeff Rudy was appointed as Chief Operating Officer of Medera in 2022. Jeff has over 30 years of clinical research and development experience across multiple therapeutic areas (infectious diseases, oncology, ophthalmology, neurology, and cardiovascular including rare diseases) at mid to large pharmaceutical companies and 9 start-up biopharmaceutical companies, including one that went to IPO

Jeff has contributed to successful approval of NDAs and BLAs and worked in all phases of development (preclinical/pre-candidate; early, mid and full development; and commercial launch and post-marketing). He has worked on advanced therapies (cell and gene therapy) at several start-up biotech companies, serving on the senior executive teams as Chief Operating Officer and Vice President of Clinical Operations and Research & Development Operations in the past 15 years.

He has held positions of increasing responsibility at Pfizer, Gilead Sciences, Cell Genesys and Amgen in the past